Back to Search Start Over

APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale

Authors :
Barry I. Freedman
Marva M. Moxey-Mims
Amir A. Alexander
Brad C. Astor
Kelly A. Birdwell
Donald W. Bowden
Gordon Bowen
Jonathan Bromberg
Timothy E. Craven
Darshana M. Dadhania
Jasmin Divers
Mona D. Doshi
Elling Eidbo
Alessia Fornoni
Michael D. Gautreaux
Rasheed A. Gbadegesin
Patrick O. Gee
Giselle Guerra
Chi-yuan Hsu
Ana S. Iltis
Nichole Jefferson
Bruce A. Julian
David K. Klassen
Patrick P. Koty
Carl D. Langefeld
Krista L. Lentine
Lijun Ma
Roslyn B. Mannon
Madhav C. Menon
Sumit Mohan
J. Brian Moore
Barbara Murphy
Kenneth A. Newell
Jonah Odim
Mariella Ortigosa-Goggins
Nicholette D. Palmer
Meyeon Park
Afshin Parsa
Stephen O. Pastan
Emilio D. Poggio
Nishadi Rajapakse
Amber M. Reeves-Daniel
Sylvia E. Rosas
Laurie P. Russell
Deirdre Sawinski
S. Carrie Smith
Mitzie Spainhour
Robert J. Stratta
Matthew R. Weir
David M. Reboussin
Paul L. Kimmel
Daniel C. Brennan
Source :
Kidney International Reports, Vol 5, Iss 3, Pp 278-288 (2020)
Publication Year :
2020
Publisher :
Elsevier, 2020.

Abstract

Introduction: Much of the higher risk for end-stage kidney disease (ESKD) in African American individuals relates to ancestry-specific variation in the apolipoprotein L1 gene (APOL1). Relative to kidneys from European American deceased-donors, kidneys from African American deceased-donors have shorter allograft survival and African American living-kidney donors more often develop ESKD. The National Institutes of Health (NIH)–sponsored APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is prospectively assessing kidney allograft survival from donors with recent African ancestry based on donor and recipient APOL1 genotypes. Methods: APOLLO will evaluate outcomes from 2614 deceased kidney donor-recipient pairs, as well as additional living-kidney donor-recipient pairs and unpaired deceased-donor kidneys. Results: The United Network for Organ Sharing (UNOS), Association of Organ Procurement Organizations, American Society of Transplantation, American Society for Histocompatibility and Immunogenetics, and nearly all U.S. kidney transplant programs, organ procurement organizations (OPOs), and histocompatibility laboratories are participating in this observational study. APOLLO employs a central institutional review board (cIRB) and maintains voluntary partnerships with OPOs and histocompatibility laboratories. A Community Advisory Council composed of African American individuals with a personal or family history of kidney disease has advised the NIH Project Office and Steering Committee since inception. UNOS is providing data for outcome analyses. Conclusion: This article describes unique aspects of the protocol, design, and performance of APOLLO. Results will guide use of APOL1 genotypic data to improve the assessment of quality in deceased-donor kidneys and could increase numbers of transplanted kidneys, reduce rates of discard, and improve the safety of living-kidney donation. Keywords: African Americans, APOL1, chronic kidney disease, graft failure, kidney transplantation, outcomes

Details

Language :
English
ISSN :
24680249
Volume :
5
Issue :
3
Database :
Directory of Open Access Journals
Journal :
Kidney International Reports
Publication Type :
Academic Journal
Accession number :
edsdoj.27ee292381584280a69fe14f4d3b0d74
Document Type :
article
Full Text :
https://doi.org/10.1016/j.ekir.2019.11.022